Off-label use in palliative medicine

被引:0
作者
Remi, Constanze [1 ]
Gerlach, Christina [2 ]
机构
[1] Klinikum Univ Munchen, Klin & Poliklin Palliat Med, Arzneimittelinformat, Marchioninistr 15, D-81377 Munich, Germany
[2] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin Onkol Hamatol Knochenmark Tra, Abt Pneumol, Bereich Palliat Med,Zentrum Onkol 2, Hamburg, Germany
来源
SCHMERZ | 2021年 / 35卷 / 01期
关键词
Hospices; Terminal care; Drug approval; Remuneration; drug therapy; Documentation; treatment; Palliative Care;
D O I
10.1007/s00482-020-00522-5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Palliative care serves to improve the quality of life in patients suffering from incurable diseases. Pharmacotherapy of distressing symptoms plays an important role. Off-label use refers to the use of drugs outside the marketing authorization. In addition to the indications off-label use may also be due to duration of treatment, route of administration and the admixture of substances. Off-label use is common in palliative and hospice care and is probably unavoidable in many cases. For treatment planning and realization of off-label therapy in clinical practice, patient-related aspects, information, therapy monitoring and documentation of therapy effects should be considered in addition to drug-related information. Only in this way it is possible to offer a scientifically adequate, appropriate and economic therapy that is linked to an appropriate risk-benefit ratio for the individual patient. Due to the lack of authorization studies, reporting is of particular importance.
引用
收藏
页码:61 / 73
页数:13
相关论文
共 22 条
[11]   Advances in Pathogenesis and Management of Pruritus in Cholestasis [J].
Kremer, Andreas E. ;
Bolier, Ruth ;
van Dijk, Remco ;
Elferink, Ronald P. J. Oude ;
Beuers, Ulrich .
DIGESTIVE DISEASES, 2014, 32 (05) :637-645
[12]  
leitlinienprogramm-onkologie, Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK (2023) AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL
[13]   Systematic review and meta-analysis of cannabinoids in palliative medicine [J].
Muecke, Martin ;
Weier, Megan ;
Carter, Christopher ;
Copeland, Jan ;
Degenhardt, Louisa ;
Cuhls, Henning ;
Radbruch, Lukas ;
Haeuser, Winfried ;
Conrad, Rupert .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2018, 9 (02) :220-234
[14]  
R?mi, 2018, ARZNEIMITTELTHERAPIE
[15]  
Remi C., 2020, Zum Umgang mit Off-Label-Use in der Palliativmedizin, V2
[16]  
Reyna YZBM., 2007, RES METHODS PALLIATI
[17]   Evidence based medicine: What it is and what it isn't - It's about integrating individual clinical expertise and the best external evidence [J].
Sackett, DL ;
Rosenberg, WMC ;
Gray, JAM ;
Haynes, RB ;
Richardson, WS .
BRITISH MEDICAL JOURNAL, 1996, 312 (7023) :71-72
[18]   Off-label drug use in oncology: a systematic review of literature [J].
Saiyed, M. M. ;
Ong, P. S. ;
Chew, L. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (03) :251-258
[19]   Regulating off-label drug use - Rethinking the role of the FDA [J].
Stafford, Randall S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (14) :1427-1429
[20]  
Stander S, S2K LEITLINIE DIAGNO